Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs PE 0139 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors PhaseBio Pharmaceuticals
- 10 Mar 2017 Status changed from active, no longer recruiting to completed.
- 16 Nov 2016 Planned End Date changed from 1 Aug 2016 to 1 Nov 2017.
- 16 Nov 2016 Status changed from recruiting to active, no longer recruiting.